raltegravir + maraviroc + efineptakin alfa

This combination therapy, evaluated in the ERAMUNE-01 clinical trial, consists of antiretroviral therapy (ART) intensification using raltegravir and maraviroc, paired with the immunomodulatory agent efineptakin alfa (recombinant human interleukin-7). Raltegravir is an HIV-1 integrase strand transfer inhibitor that prevents the integration of viral DNA into the host genome, while maraviroc is a CCR5 co-receptor antagonist that blocks viral entry into CD4+ T-cells. Efineptakin alfa (CYT107) is a cytokine that stimulates the expansion and survival of T-cells. The strategy was developed by the non-profit organization Objectif Recherche VACcin Sida (ORVACS) to target the latent HIV-1 reservoir in patients with long-term viral suppression, aiming to reduce the pool of infected cells that persist despite standard ART.

Brand names

IsentressSelzentry

Other names

ART intensification + IL-7r-hIL-7r-hIL7r-hIL 7recombinant human interleukin-7CYT107 + raltegravir + maravirocERAMUNE-01 interventionERAMUNE01 interventionERAMUNE 01 intervention